PDF(Pubmed)
Abstract：
Aim: To assess the relative efficacy of disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS) including newer therapies (ozanimod, ponesimod, ublituximab) using network meta-analysis (NMA). Materials & methods: Bayesian NMAs for annualised relapse rate (ARR) and time to 3-month and 6-month confirmed disability progression (3mCDP and 6mCDP) were conducted. Results: For each outcome, the three most efficacious treatments versus placebo were monoclonal antibody (mAb) therapies: alemtuzumab, ofatumumab, and ublituximab for ARR; alemtuzumab, ocrelizumab, and ofatumumab for 3mCDP; and alemtuzumab, natalizumab, and either ocrelizumab or ofatumumab (depending on the CDP definition used for included ofatumumab trials) for 6mCDP. Conclusion: The most efficacious DMTs for RMS were mAb therapies. Of the newer therapies, only ublituximab ranked among the three most efficacious treatments (for ARR).
摘要：
目的：评估疾病修饰疗法（DMT）对复发性多发性硬化症（RMS）的相对疗效，包括更新的疗法（ozanimod，ponesimod,ublituximab)使用网络荟萃分析(NMA)。材料和方法：进行了年度复发率（ARR）和3个月和6个月确认的残疾进展时间（3mCDP和6mCDP）的贝叶斯NMA。结果：对于每个结果，与安慰剂相比，三种最有效的治疗方法是单克隆抗体（mAb）治疗：Ofatumumab,和ublituximab用于ARR；阿仑单抗，奥克瑞珠单抗，和Ofatumumab用于3mCDP；和阿仑单抗，那他珠单抗,6mCDP的奥利珠单抗或奥曲单抗(取决于纳入的奥曲单抗试验中使用的CDP定义).结论:对RMS最有效的DMT是mAb疗法。在较新的疗法中，只有ublituximab在三种最有效的治疗方法中排名（对于ARR）。
